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The endoplasmic reticulum (ER) is a major site of passage for proteins en route to other
organelles, to the cell surface, and to the extracellular space. It is also the transport route for
peptides generated in the cytosol by the proteasome into the ER for loading onto major his-
tocompatibility complex class I (MHC I) molecules for eventual antigen presentation at the
cell surface. Chaperones within the ER are critical for many of these processes; however,
outside the ER certain of those chaperones may play important and direct roles in immune
responses. In some cases, particular ER chaperones have been utilized as vaccines against
tumors or infectious disease pathogens when purified from tumor tissue or recombinantly
generated and loaded with antigen. In other cases, the cell surface location of ER chaper-
ones has implications for immune responses as well as possible tumor resistance.We have
produced heat-shock protein/chaperone protein-based cancer vaccines called “chaperone-
rich cell lysate” (CRCL) that are conglomerates of chaperones enriched from solid tumors
by an isoelectric focusing technique.These preparations have been effective against numer-
ous murine tumors, as well as in a canine with an advanced lung carcinoma treated with
autologous CRCL.We also published extensive proteomic analyses of CRCL prepared from
human surgically resected tumor samples. Of note, these preparations contained at least 10
ER chaperones and a number of other residents, along with many other chaperones/heat-
shock proteins. Gene ontology and network analyses utilizing these proteins essentially
recapitulate the antigen presentation pathways and interconnections. In conjunction with
our current knowledge of cell surface/extracellular ER chaperones, these data collectively
suggest that a systems-level view may provide insight into the potent immune stimulatory
activities of CRCL with an emphasis on the roles of ER components in those processes.
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INTRODUCTION
The endoplasmic reticulum (ER) is an organelle of new begin-
nings, sudden endings, twists, turns and connections, major
changes, and passage to new places. During protein translation,
nascent proteins destined for the ER or other locations along the
secretory route protrude an appropriate“signal sequence”from the
ribosome that the signal recognition particle (SRP) distinguishes
as an ER address label (1). After the SRP binds to the peptide, it
tethers the ribosome near the SRP receptor on the ER membrane.
The ribosome docks with the SEC61 complex for co-translation
of the rest of the protein across the ER membrane (2, 3). Once in
the ER, chaperone-based folding occurs, along with glycosylation,
disulfide bond formation, and transport out of the ER into the
Golgi if such address labels are found in the newly minted pro-
tein (4). These activities require calcium, and the ER (along with
mitochondria) is the major calcium storage compartment in a
typical cell. Many of the chaperones are calcium-binding proteins
with extensive capacity; this plays into their functions, as well as to
other calcium-essential units in the cell (5). The oxidizing environ-
ment of the ER lumen promotes disulfide bridge formation, largely
via protein disulfide isomerase (PDI/PDIA) family members, and
these bonds are likely critical in the proper folding of individual
proteins and in formation of multi-subunit complexes (6). The
ER has numerous quality control (ERQC) mechanisms to assure
properly folded proteins exit the ER for other destinations, but
may essentially end in ER-associated degradation (ERAD) (7).
Proteins that do not achieve the appropriate tertiary or quater-
nary confirmations are considered terminally misfolded and are
poly-ubiquitinated (in a complex fashion) with retrotransloca-
tion to the cytosol for proteasomal degradation (8). The efficiency
of entry, exit, and arrival at the final destination varies dramati-
cally for different proteins and ranges from nearly 100% “success”
(i.e., amount of a given protein entering the ER compared to the
amount of that protein reaching its final localization, such as the
cell surface) to as low as 25% (9). The lumenal environment of
the ER is most akin to the cell’s exterior, and the ER is a portal
connecting the cytosol to the cell surface and beyond.
The chaperones of the ER are critical to many aspects of ER
function, whether in protein folding modes, as calcium binders,
as sensors of stress such as the unfolded protein response (10), or
due to cell-surface localization or extracellular release, as immune
modulators (11–18). These latter characteristics combine with the
protein- and peptide-binding/carrying capacity of chaperones to
allow for their utilization as vaccines, particularly in oncology
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Table 1 | Chaperone proteins described herein and their subcellular localizations.
Subcellular localization
Protein common name Gene name Endoplasmic
reticulum/Golgi
Cytosol Nucleus Mitochondria Lysosome Cell surfacea
HSP27b HSPB1 X X X
HSP47 (serpin H1) SERPINH1 X X
HSP60 HSPD1 X X X
HSP70 HSPA1A/B X X X X
HSC70 HSPA8 X X X X
GRP78 (BiP) HSPA5 X X X X X
HSP90 HSP90AA/B1 X X X
HSP110 HSPH1 X X X
GRP94 (gp96) HSP90B1 X X X
GRP170 (ORP150) HYOU1 X X
PDI/PDIAc P4HB X X
CRT/CALR CALR X X X
Chaperones in this article and their subcellular localizations. This is a list of the chaperone proteins and their gene names mentioned in this article annotating their
known subcellular localizations.
aCell-surface localization is most often associated with tumor cell surfaces.
bMurine version is often called HSP25.
cThere are muliple PDI (protein disulfide isomerase) family members too numerous to include here.
(19–22). This review will highlight the multifaceted roles of the
ER in immunity, and will then focus on how chaperones from
the ER may contribute to immune responses under “exogenous”
circumstances, e.g., once outside the cell. We will further discuss
how such chaperones may contribute to anti-cancer immunity in a
complex vaccine like chaperone-rich cell lysate (CRCL). As we will
discuss a number of chaperone proteins from various subcellular
locations beyond those of the ER, we have prepared Table 1 to aid
in keeping track of these proteins.
THE ENDOPLASMIC RETICULUM AS A CONDUIT TO
IMMUNITY: T CELLS “SEE INTO THE SOUL” OF A CELL
The mammalian immune system has developed a largely “non-
invasive” means of assessing the immune status of most of the host
organism’s cells. Immune effector cells of both the adaptive arm
(i.e., CD4+ and CD8+ T cells) and the innate arm [e.g., natural
killer (NK) cells] monitor cell surfaces by engaging major histo-
compatibility complex class I and II (MHC I and II) molecules
in the case of T cells (23–25) and damage-associated molecular
patterns (DAMPs) (26), as well as stress ligands such as MICA/B
and ULBP families (27) in the case of NK cells. NK cells also bal-
ance activating and inhibitory receptor stimulation that may be
present on normal cells, or downregulated or absent on abnor-
mal cells, such as loss of MHC I (28). Perturbations that occur in
the cytosol such as pathogenic infection or the genetic, proteomic,
and metabolic disarray of neoplasia may lead to the expression of
non-self proteins or of mutated self proteins. These, along with
other “normal” but obsolete proteins are poly-ubiquitinated and
are targeted for degradation into short peptides by the proteasome.
With additional trimming (or outright proteasome-independent
generation) possible by cytosolic peptidases, peptides enter the
ER through the TAP transporters (transporters associated with
antigen processing; ABC family members). There, the peptides
may be further pruned before chaperone-assisted loading onto
MHC I molecules, which are then packaged for transit to the cell
surface. Display of peptides in the context of MHC I molecules
provides the reading frame for CD8+ T cells that determine the
normal or abnormal status of the presenting cell.
MHC II display and presentation generally only occurs in spe-
cialized immune cells known as professional antigen-presenting
cells (APCs), such as macrophage, dendritic cells (DCs), and B
cells (29). However, MHC II expression can occur on other cells
such as endothelial cells following IFNγ exposure (30) or on neu-
ronal cells in peripheral neuropathies (31), turning such cells
into APCs. Exogenous antigens are engulfed at the cell surface
into endosomal/phagosomal vesicles (32) where denaturation and
degradation of proteins begins. Meanwhile, MHC II molecules are
assembled in the ER with a “placeholder” in the peptide-binding
cleft, the chaperone invariant chain (Ii). The MHC II molecules
enter vesicles and are released into the cytosol’s endocytic pathway
where the Ii is cleaved to class II-associated invariant chain peptide
(CLIP). These vesicles encounter the late endocytic/phagocytic
vesicles with lysosomal characteristics where CLIP is displaced by
peptides with higher affinity for the MHC binding pocket. These
are often called MHC II compartments (MIICs), and the vesi-
cles eventually deliver MHC II to the cell surface for presentation
to CD4+ T cells (33) for the latters’ assessments of the immune
status of the presenting cell. Recent work with the MHC II process
describes more complicated routes and alternatives, and some
of this information will re-appear in our discussion of antigen
cross-presentation (34, 35).
Thus, CD4+ and CD8+ T cells scan cell surfaces for the MHC-
displayed peptides that may indicate a pathologic state within
those cells; however, the T cells require activation and “education”
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concerning the nature of the problem. Professional APCs serving
as scavenger cells may have confronted a situation with cell/tissue
damage that resulted in the APCs engulfing extracellular material.
If this occurred in an inflammatory environment in the presence
of released “danger signals” (36, 37), the APCs become stimulated
to provide “signal one” and “signal two” to T cells (38, 39). The
first signal is the MHC-restricted peptide that is capable of trig-
gering a T-cell receptor (TCR) specific for that particular peptide
in that particular MHC peptide-binding cleft; the assumption is
that the peptide is indicative of the distress (infection, mutation)
in the donor cell before acquisition by the APC. The second sig-
nal comes from the expression of co-stimulatory molecules by the
APC, such as CD80/CD86, that provide activation impetus for T
cell. The interface between APC and T cell in this scenario is called
the “immunological synapse” (40). After recognition of antigen,
activation, and stimulation, the T cells exit the lymph node and
enter the periphery to search for affected cells that display the
antigens that indicate disease (i.e., the same ones that triggered the
TCRs originally).
In the scenario described, APCs acquire exogenous antigens
that are displayed to T cells; the classical mode of antigen uptake
and display by MHC in this trafficking pathway is via MHC II,
which would induce only a CD4+ T-cell response. However, it is
clear that APCs also display foreign and self peptides on MHC I
molecules, called “cross-presentation” (41). The endosomal traf-
ficking of endocytosed proteins, particularly in professional APCs,
can direct such vesicles away from lysosomal degradation; pep-
tide generation within endosomes may allow for direct loading
of vesicle-bound MHC I molecules (42). On the other hand, the
proteins or peptides could passage out of the vesicles and into
the cytosol for proteasomal processing and entry into the classical
MHC I pathway. These peptides could also passage back into endo-
somes via endosomal TAP transporters; if MHC I molecules are in
those vesicles, the peptides may be loaded onto the presentation
proteins (42).
Through these various mechanisms, which start with the
assembly of MHC molecules in the ER, T cells may be stimu-
lated to respond to a pathogenic state, and during surveillance
are able to determine the internal stasis or possible malcontented
nature of the MHC-presenting cell. The “outside-looking-in” for-
mat does not require destruction of the presenting cell, unless that
cell displays antigens indicative of a pathogenic state.
CHAPERONES ON THE ROOF: CELL-SURFACE CHAPERONES
IN IMMUNITY
Roles of chaperones in the antigenicity of foreign, and possibly
self peptides and proteins, are usually associated with extracel-
lular chaperones as danger signals (36, 37, 43–45). The strong
sequence and structural relationships between chaperones from
primitive and more advanced organisms (46) suggest that immune
reactivity that evolved against bacterial chaperones may lead to
cross-reactivity with mammalian chaperones [e.g., Ref. (47)], but
those outcomes are varied (48). Binding to pattern recognition
receptors such as Toll-like receptors (TLRs) is a characteristic of
extracellular chaperones, both mammalian and bacterial (49, 50)
but TLR stimulation may, at least in some cases, result from bacte-
rial PAMPs associated with the chaperones (51). Nonetheless, the
innate immune signaling aspects of chaperones outside the cell
are likely the key initial mediator steps in promoting an immune
response.
Cell-surface display of chaperones represents a special case of
re-localized chaperones capable of provoking immune responses.
In oncology, membrane HSP70 is one of the most heavily stud-
ied (52), where a 14-mer region of the chaperone is recognized
as a target for NK cells (53). The mechanism for the HSP70’s
membrane association remains unclear, although its interactions
with negatively charged phospholipids may play a role (54), with
involvement of particular domains of the protein (55). The “large”
relative of HSP70, HSP110 (22), has been noted on the surfaces
of brain tumor cell lines (15, 16), but the implications of this
localization are unknown.
The small heat-shock protein HSP27 (HSP25 in mice) was one
of the number of chaperone proteins found on tumor cell sur-
faces by proteomic analyses (56), as well as by flow cytometry
(15). The immune responses to surface HSP27 remain unclear,
but murine mammary cancer cells selected for cell-surface expres-
sion of HSP25 proliferated faster and exhibited more frequent lung
metastatic lesions than cells with lower or minimal surface HSP25
display (57). Interestingly, in those immune-competent animals,
heat-shock-driven inducible HSP70 surface expression on those
cells resulted in reduced metastatic growth and overall increased
survival compared to implantation of cells with low surface HSP70
expression, suggesting that immune responses may play a role,
perhaps via NK cells (53).
HSP90 was one of the original chaperones found to be a
“tumor-specific transplantation antigen” (TSTA) potentially use-
ful as a vaccine when purified from tumors (58), and was shown
to be present on murine MethA tumor cell surfaces. The surface
expression was discovered on other tumor cell lines as well (59).
Surface HSP90 interacts with HER2 and mediates tumor cell inva-
siveness on breast cancer cells (60), and blocking surface HSP90
activity with a cell-impermeant inhibitor or antibodies validates
this in other tumor types (61–63). The chaperone was also iden-
tified on the surfaces of CNS/neuronal-derived tumors (15, 64),
where expression on spheroid lines was higher (64). Since the
growth of CNS tumors in “stem cell-like” cultures (that frequently
form spheroids) is a relatively new phenomenon, HSP90 surface
expression may need to be re-examined for those tumors. As men-
tioned above, tumor-surface HSP70 is a known NK cell target,
but both surface HSP70 and HSP90 are also gamma–delta T-cell
targets, at least in EBV-transformed B cells (65, 66).
While the mechanisms of cell-surface display for chaperones
considered to be canonically localized to the cytosol (or nucleus,
in some cases) remain puzzling, one can imagine a simpler route
to the cell surface for chaperones originally localized to the ER.
As they are residents of the compartment of origin for proteins
destined for cell-surface expression or extracellular release, their
passage out of the ER requires bypassing KDEL receptors. These
are proteins in pre- or cis-Golgi compartments that recognize the
lys–asp–glu–leu (KDEL) motif present on most ER resident pro-
teins. Those proteins that progress from the ER into the Golgi
compartments are recognized and bound by the family of KDEL
receptors that then engage in retrograde transport to return the
KDEL-containing proteins to the ER (67).
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Of the cell surface-expressed ER chaperones, GRP78 (BiP) is
one of the best characterized and was noted on the surfaces of
a hybrid neuroblastoma cell line in the late 1990s (68) (and has
been found on other CNS/neurologic tumors) (15, 16). GRP78 was
also one of the chaperone proteins identified on tumor cell sur-
faces in a proteomic study (56) (along with other HSP70 family
members, and HSPs 27, 47, and 60, and PDI members). GRP78’s
chaperone capacity, apparently still intact on the cell surface, was
used to target pro-apoptotic peptides fused to consensus GRP78
binding motifs resulting in cell death and reduced model tumor
growth (69) [and further reviewed here (70)]. At the cell sur-
face, GRP78 acts as a receptor or in complexes with numerous
partners that may promote cell survival or engage in apoptosis
(71). Surface GRP78 is a therapeutic antibody target (72, 73),
but in some cases antibodies in patient sera bind to activated α2-
macroglobulin’s agonist site on its receptor GRP78. This leads to
tumor cell growth stimulation and apoptosis prevention (74). In
general, tumor-surface GRP78 is indicative of enhanced malignant
tumor phenotypes (71).
GRP94 (also called gp96, endoplasmin, ERp99), is the ER
HSP90 paralog. Like HSP90, it was identified as a “tumor rejection
antigen” (TRA) purified from MethA and CMS5 murine sarcomas
(75), and was found in plasma membrane fractions and on murine
and human tumor cell surfaces (76–78). The function of surface
GRP94 is not entirely clear, but it appears to play a role in the
processing of surface metalloproteinases (79). Immunologically,
surface GRP94 can activate DCs, inducing a pro-inflammatory
state with activation of tumor-specific T cells (80).
Despite its prominent role as an ER chaperone cancer vaccine
(81), GRP170/ORP150 has only rarely been cited as a cancer cell-
surface protein (15, 82), but it has been identified on mouse egg
oolemma (83) as well as human sperm surfaces (84, 85). Other ER
residents such as ERp5/PDI6 (PDI family) are present on tumor
cell surfaces; in this case, the chaperone is involved in the release
of the NK cell activating receptor MICA from tumor cell surfaces,
presumably as a protective measure to avoid NK attack. PDI also
functions in the shedding of tumor endothelial maker 5 (TEM5)
with potential impacts on cell adhesion and migration (86). PDI
and calreticulin were among the KDEL-containing proteins pre-
viously identified as surface components of the NG108-15 cell
line (68). PDI family members had been identified as localized
to platelet surfaces as early as 1995 (87) and were later shown
to be on B-CLL cells (88). PDI plays a role in glioma xenograft
tumor invasiveness (89). Roles for surface PDIs include transni-
trosation and nitric oxide metabolism (86) and formation of thiols
on cell-surface proteins (90).
Calreticulin (CRT; CALR) is considered as an ER chaperone,
but with very divergent intracellular, cell-surface, and extracellu-
lar localizations (91). It was identified with cell surfaces as early
as 1995 (92, 93), and is regarded as a major immunologic player
whose surface exposure promotes the immunogenicity of tumor
cells dying by particular chemotherapy agents (94). CRT was
already known as a tumor peptide-carrying cancer vaccine candi-
date (95–97), but in these scenarios of (normally immune-silent)
apoptotic cell death, it is viewed as an engulfment signal for phago-
cytic cells such as macrophage and DCs (98, 99). While CRT is
clearly present on numerous cell types, including cancers (15, 91),
those cells may resist APC interactions and phagocytosis via CD47
(98, 100). These studies strongly suggest that how tumor cells
die matters greatly to the immune system, and delineate potential
avenues of improved therapy.
Thus, cell-surface localization of various chaperone proteins,
while originally quite controversial, is now accepted, and seems to
associate with cancer pathology. The roles of surface chaperones
in anti-tumor immunity may be complicated in terms of putative
function favoring the tumor’s growth versus serving as immune
attractants; perhaps, this balance can somehow be shifted toward
effective immune responses.
CHAPERONES OUTSIDE: EXTRACELLULAR CHAPERONES IN
IMMUNITY
As mentioned above, we have few well-understood mechanisms
for the localization of cytosolic chaperones/heat-shock proteins to
the cell surface. Similarly, we know little about the release of such
chaperones outside the cell (101, 102), despite nearly three decades
of research. ER chaperones are already in the secretory pathway,
so bypassing KDEL receptors could explain that release. Another
mechanism from the cytosol or the ER could involve vesicular
release via endolysosomes (103, 104) or by extracellular vesicles
(exosomes, microvesicles) (15, 105). While there may be a number
of functional roles for extracellular chaperones such as extracel-
lular signaling (106), chaperoning extracellular matrix compo-
nents (107, 108), and general cytoprotection during injury (109)
or in proteostasis (110), much of the research on extracellular
chaperones concerns their roles in immunity.
We noted above that the immune properties of extracellular
chaperones are intrinsically related to those proteins acting as dan-
ger signals when they interact with innate immune cells (111, 112).
This stimulatory capacity at a distance is reminiscent of cytokines,
and thus led to the term “chaperokine” (113), with particular
involvement of cellular TLRs. Extracellular chaperones such as
HSP27 (114), HSP60 (115), HSP70 (14), GRP94 (116), HSP90,
and GRP170 (117) have all been shown to bind TLRs. Other chap-
erone receptors include molecules such as CD14, CD36, CD40,
LOX1, scavenger receptors SR-A and SREC-1, and CD91 (also
called LRP1 and A2MR, the α2-macroglobulin receptor) (118).
Thus, innate immune cells, APCs, and a number of other cell types
possess receptors implicated in binding extracellular chaperones
presumably released by cells under stressful circumstances.
In the area of cancer immunotherapy, the concept of cancer
cells producing and releasing chaperones as a form of “auto-
vaccination” is an attractive one, and there have been a number
of attempts to generate tumor cell lines producing secretable ver-
sions of immunogenic chaperones. An example of this is the ER
resident vaccine candidate GRP170 (also called ORP150) (22),
which has demonstrated danger signal capacity if secreted outside
the cell (45) and has been shown to chaperone whole proteins in
that secretable form that are antigenic (119). This links the innate
immune stimulation by chaperone proteins with the adaptive (tar-
geted) response and demonstrates how chaperones released by or
derived from pathogenic tissues may possess both adjuvant and
antigen. Numerous other chaperones have been engineered or
designed for secretion from tumor cells [reviewed here (120)],
including GRP78, which was previously regarded as ineffective as
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a cancer vaccine (121). The use of an allogeneic tumor cell vaccine
with secretable GRP94 (AD100-gp96-Ig) in clinical trials has been
reported (122). Putative benefits of this latter form of a vaccine
include the “off-the-shelf” utility (i.e., the vaccine may be used on
essentially any patient and does not need to come from autol-
ogous tumor), the “host versus graft” immune cross-reactivity
with the allogeneic cells, and the “continuous-release format” of
the GRP94 as an advantage in stimulating immune responses in
contrast to the bolus effect from an injectable vaccine. One dis-
advantage would be the lack of true personal, individual patient
tumor-specific antigens available from an autologous preparation,
and the constant need for reassurance that the tumor cells were
not proliferating.
The presence of chaperones in the extracellular milieu, by
intent, or by stress, or damage, offers insight into the biology of
the sensation of danger by the immune system, as well as poten-
tial practical applications from a vaccine perspective. Our next
section will discuss chaperone protein-based cancer vaccines, with
an emphasis on ER proteins as components of those vaccines.
CHAPERONES AS VACCINES: LONE WOLVES AND GETTING
THE WAGONS IN A CRCL
The release of chaperones extracellularly, whether by bio-
engineering, induced stress, or immune-noticeable forms of cell
death, may be reenacted in vaccine scenarios where chaperones are
purposefully extracted from tumor cells/tissues and re-introduced
to patients, typically by parenteral administration. Benefits in this
situation include known dosages, ability to monitor local reac-
tions [e.g., delayed-type hypersensitivity (DTH) responses], and
the ability to directly enhance APC activation and migration with
topical applicants such as imiquimod (123). Depending on the
type of vaccine generated, if the source is a tumor sample, that
may become the limiting reagent (124, 125), the heterogeneity
of tumors may make accurate “dosing” (i.e., how much of the
chaperone is actually from the tumor) more difficult. Nonetheless,
patient tumor-derived GRP94/gp96 as an autologous therapeutic
vaccine has progressed the farthest in various clinical trials, start-
ing in 2000 [reviewed here (126)] and has since included trials for
patients with colorectal and pancreatic cancers, melanoma, non-
Hodgkin’s lymphoma, renal cell carcinoma, and continues with
Phase II trials for patients with high grade gliomas. The prod-
uct is currently owned by Agenus1, and has gone by HSPPC-96,
Oncophage, Vitespen, and currently, Prophage. A major attrac-
tive feature has been the low incidence of deleterious side effects,
and it has received regulatory approval in Russia for patients at
intermediate risk for disease recurrence of renal cell carcinoma,
the first such cancer vaccine approved anywhere (127). However,
further European Union approval was unsuccessful, where the
agency cited, among other issues, a lack of identified antigenic pep-
tides associated with the vaccine preparations2. Other heat-shock
protein vaccines are also at clinical trial stages (e.g., the HSP110–
gp100 complex, NCT01744171)3, including one that induces HSPs
1http://www.agenusbio.com/
2http://www.ema.europa.eu/docs/en_GB/document_library/Application_
withdrawal_assessment_report/2010/03/WC500075459.pdf
3www.clinicaltrials.gov
by inflicting cryoablation or radiofrequency ablation on tumors
(NCT00568763) rather than the direct use of individual HSPs as
vaccines.
A question that frequently arises in these cancer vaccine sce-
narios regards the generation of autoimmunity. To some extent,
that is indeed the goal of cancer immunotherapy, targeting a tissue
that is largely “self.” However, the immune suppressive activities
of most cancers likely prevent anti-tumor activity as well as true
autoimmune activity. Current immune “checkpoint inhibitors”
such as antibodies against CTLA-4 (ipilimumab) that prevent
T-cell repression have driven potent anti-tumor responses, but
also occasional significant autoimmunity (128). However, such
autoimmune responses have not been noted in chaperone-based
anti-cancer vaccines (129, 130), but as combination therapies will
start utilizing such checkpoint inhibitors (131), vigilance will be
essential.
The concept of a multiple-chaperone vaccine arose from the
thought that dying cells release entire cohorts of proteins rather
than purified batches of individual ones. CRCL is such a multi-
chaperone vaccine preparation that initially was shown to contain
the four known immunogenic chaperones of that time: HSP70,
HSP90, GRP94, and calreticulin (132). The rationale was that
these four chaperones, from the cytoplasmic and ER compart-
ments, would likely contain a broader repertoire of tumor anti-
gens from an autologous source, and possibly provide greater
APC stimulation than single chaperone vaccines. Rather than
purification, CRCL preparation utilized a free solution-isoelectric
focusing (FS-IEF) technique that resulted in a large, highly cohe-
sive complex of hundreds of proteins (97, 133). This complex
activated DCs yielding high expression of CD40 and MHC I
and release of IL-12, resulting in highly stimulated T cells (134,
135). This APC stimulation remained effective even in the face
of regulatory T cells (Tregs) (136). Additional studies showed
that CRCL-stimulated APCs upregulated CD70, NFκB, and iNOS,
along with NO, TNFα, and RANTES production, and enhanced
phosphorylation of STAT1 and STAT5, and activation of the AKT
and MAPK pathways (137). Depletion of chaperones diminished
CRCL’s immune properties (134). Immunological testing demon-
strated the presence of the BCR–ABL fusion peptide in CRCL
derived from BCR–ABL positive tumors that resulted in peptide-
specific responding T cells (138), and further biochemical and pro-
teomic work identified nearly 60 peptides associated with CRCL
(139). When used pre-clinically as a single agent in prophylactic
and therapeutic vaccination schemes, or as an antigen source for
DC vaccines, or in combination with other treatment regimens,
CRCL was found effective against numerous murine hematologic
malignancies, and against melanoma, fibrosarcoma, breast cancer,
and brain tumor models (15, 97, 134, 140–144). CRCL was also
shown to drive NK cell pro-inflammatory cytokine and chemokine
release (145) as well as bioactive anti-tumor antibody production
(143). CRCL, combined initially with the topical TLR stimulant
imiquimod, was used as the sole post-surgical therapeutic agent
to treat an aggressive metastatic lung cancer in a canine patient
(146); the dog’s prognosis was <4 weeks survival, but she survived
for 11 months with CRCL treatment. Finally, CRCL is a compo-
nent of an immunotherapy regimen currently in clinical trials
(NCT01998542, NCT01995227).
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Table 2 | ER/ER-associated proteins identified in a previous proteomic
study of human CRCL.
ID Symbol Entrez gene name
Q6DD88 ATL3 Atlastin gtpase 3
P27797 CALR Calreticulin
P27824 CANX Calnexin
O14735 CDIPT CDP-diacylglycerol – inositol
3-phosphatidyltransferase
Q9UKY3 CES1P1 Carboxylesterase 1 pseudogene 1
Q99653 CHP1 Calcineurin-like EF-hand protein 1
Q9BUN8 DERL1 Derlin 1
Q7Z2K6 ERMP1 Endoplasmic reticulum metallopeptidase 1
P30040 ERP29 Endoplasmic reticulum protein 29
Q9BS26 ERP44 Endoplasmic reticulum protein 44
P30443 HLA-A Major histocompatibility complex, class I, A
D3U3L9 HLA-B Major histocompatibility complex, class I, B
A5D8×1 HLA-C Major histocompatibility complex, class I, C
P14625 HSP90B1 Heat-shock protein 90 kDa beta (grp94),
member 1
P11021 HSPA5 Heat-shock 70 kDa protein 5
(glucose-regulated protein, 78 kDa)
Q9Y4L1 HYOU1 Hypoxia upregulated 1
P13674 P4HA1 Prolyl 4-hydroxylase, alpha polypeptide I
P07237 P4HB Prolyl 4-hydroxylase, beta polypeptide
O75340 PDCD6 Programed cell death 6
P30101 PDIA3 Protein disulfide isomerase family A,
member 3
P13667 PDIA4 Protein disulfide isomerase family A,
member 4
Q15084 PDIA6 Protein disulfide isomerase family A,
member 6
O60240 PLIN1 Perilipin 1
Q96Q06 PLIN4 Perilipin 4
P28066 PSMA5 Proteasome (prosome, macropain) subunit,
alpha type, 5
Q99436 PSMB7 Proteasome (prosome, macropain) subunit,
beta type, 7
Q06323 PSME1 Proteasome (prosome, macropain) activator
subunit 1 (pa28 alpha)
Q9UL46 PSME2 Proteasome (prosome, macropain) activator
subunit 2 (pa28 beta)
O75396 SEC22B SEC22 vesicle trafficking protein homolog B
Q15437 SEC23B Sec23 homolog B (S. cerevisiae)
P61619 SEC61A1 Sec61 alpha 1 subunit (S. cerevisiae)
(Continued)
ID Symbol Entrez gene name
Q03518 TAP1 Transporter 1, ATP-binding cassette,
sub-family B (MDR/TAP)
Q03519 TAP2 Transporter 2, ATP-binding cassette,
sub-family B (MDR/TAP)
Q04323 UBXN1 UBX domain protein 1
P09936 UCHL1 Ubiquitin carboxyl-terminal esterase L1
(ubiquitin thiolesterase)
P55072 VCP Valosin containing protein
ER and ER-associated proteins identified in a previous proteomic study of human
CRCL. Proteins were identified by gel separation, excision, digestion, and mass
spectrometry. These proteins were originally found in separate locations in this
publication (133), but were extracted and organized into this table.
Previous proteomic work to better biochemically character-
ize human CRCL preparations from various tumor types (133)
identified at least 10 known ER chaperones; re-evaluating all of
the data in that publication provided us with 36 proteins that
are from the ER or have close associations with that organelle,
such as proteasome components (Table 2). Gene ontology (GO)
assessment of those proteins using Ingenuity Pathway Analysis
(IPA) revealed canonical pathways with clear immunological rel-
evance, including antigen presentation, dendritic cell maturation
and communications, and T-cell signaling; the top 20 significantly
scoring Pathways are shown in Figure 1. There is also a high overlap
among two-thirds of the pathways (not shown).
One striking outcome from previous IPA applications was a
networks/associated functions interactome generated that showed
connectivity among various chaperones (both ER and cytoso-
lic), immune-related molecules, nuclear factors, and metabolic
enzymes (133). Focusing here on the ER components and asso-
ciated proteins, we have generated a similar interactome by com-
bining two networks with very high scores (derived from Fisher’s
exact test) that seemingly recapitulate the antigen processing path-
way for MHC Class I molecules, as well as portions of the ERAD
pathways (Figure 2). The selective entries of ER and ER-related
proteins may serve to skew the readouts from IPA, but it also sug-
gests that the ER contributions to these interactomes in particular
may play heavily into CRCL functionality.
Of the molecules included in this list but not discussed pre-
viously (133) from an immune perspective, DERL1 is a mem-
ber of the ER quality control/ERAD system, where it mediates
MHC degradation (147). It is also upregulated in tumors and
in epithelial cells exposed to tumors, where it may be involved
in angiogenesis (148). Its presence on tumor cell surfaces makes
it amenable to antibody targeting (149). ERP44, a PDI fam-
ily member, plays a controlling role in IgM assembly in B cells
(150). The perilipins play roles in the formation and transport
of lipid bodies/lipid droplets such as those formed in leukocyte
inflammatory responses (151); such lipid bodies are involved in
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FIGURE 1 |Top 20 canonical pathways derived from ingenuity
pathway analysis (IPA) gene ontology algorithms for the 36 ER and
ER-associated proteins fromTable 2. These pathways emerged
following IPA “Core Analysis.” Graph shows category scores;
“threshold” indicates the minimum significance level [scored as
−log(p-value) from Fisher’s exact test, set here to 1.25]. “Ratio”
(differential yellow line and markers) refers to the number of molecules
from the dataset that map to the pathway listed divided by the total
number of molecules that map to the canonical pathway from within
the IPA knowledgebase.
phagocytosed antigen cross-presentation in DCs (152). SEC22B,
a SNARE (soluble N -ethylmaleimide sensitive fusion attachment
protein receptor) protein, is another molecule clearly involved in
antigen cross-presentation via maturation of phagosomes (153).
SEC23B, while having no clear immune function, is a required gene
for cells with high secretory outputs (154), and not surprisingly
is overexpressed in hepatocellular carcinomas (155), and perhaps
could be regarded as an immune target. UCHL1, also called protein
gene product 9.5 (PGP9.5) has been identified as an autoantigen in
lung cancer patients (156). Thus, CRCL may contain ER proteins
besides the chaperones that may play roles in immune cells or may
act as targets of immune responses.
The extraordinary connectivity found in the interactome of
these proteins (Figure 2) suggests that there may be structural
relationships involved, and indeed bizarre structures were seen
in electron microscopy, and large particles were identified by
nanoparticle tracking analysis, in the aforementioned publication
(133). Prior to that, CRCL was shown to exist biochemically as
a large entity of virus-sized proportions by size-exclusion chro-
matography (97). Which proteins are involved, and what roles
they may play, are currently matters of speculation, but con-
ceptually a model for a “relay line” of chaperones sequentially
transferring peptides during antigen processing and presentation
has been proposed (157). There has even been validation of the
peptide transfer (158, 159), suggesting that at least close physical
proximity, if not protein–protein contact, is necessary. Nanopar-
ticles for immune stimulation, such as pathogen-like particles, are
gaining headway in vaccine research (160, 161). Perhaps, CRCL
inadvertently retains some form of particulate assembly due to its
cytoskeletal content, and carries antigens within this “cage” due to
its chaperone content. The calreticulin component of CRCL may
be an especially potent “eat me” signal for APCs, which then view
CRCL as an object with viral-like physical properties, and upon
engulfment, have endocytosed numerous antigens via the chaper-
ones, including antigens carried by the ER chaperones abundant
in CRCL.
Our “peptidomics” work with CRCL-associated peptides
implied that the protein origins of those putative antigens came
from all cellular compartments, and were high-value targets for
immune responses (139). Coupled with the proteomics work
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FIGURE 2 | Intersection of the top 2 IPA interactomes derived from the
top networks/associated functions for the 36 proteins listed in
Table 2. Proteins from table are shown in large bold font, and the protein
symbols are shown in yellow fill. “Edges” (lines) show connections
between or among molecules; solid lines indicated known direct
interactions. Dotted lines indicated indirect interactions. Dark blue lines
connect proteins from within the entry group; turquoise lines connect
proteins that were in the network but not found in our proteomic study.
Cranberry colored lines show the intersection of proteins between the
two interactomes. “Score” refers to the −log(p-value) from Fisher’s exact
score, and “Focus Molecules” are “seeds” for generation of focal points
or nodes within the network.
mentioned here (133), the GO analyses provide a basis for a sys-
tems biology approach to understanding the biochemical (and
perhaps structural) mechanisms for the success of the vaccine.
The intrinsic roles the ER-derived and -associated components
of CRCL are undoubtedly critical to the vaccine’s utility. Further
research is required to truly understand the biophysical struc-
ture of the vaccine and to determine what impact that has on
the immunological responses driven by the vaccine. The ER pro-
teins, representing the connection between the antigen-generating
cytosol, the antigen-presenting cell surface, and danger signal
activities extracellularly, are undoubtedly vital to the inherent
adjuvant/antigen formulation that is CRCL.
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